… This study aims to investigate the dosage pattern, efficacy, and safety of sacubitril/valsartan
(Sac/Val) in Chinese heart failure with reduced ejection fraction (HFrEF) patients regarding …

… Its efficacy and safety in end stage renal disease … in HD patients who received ARNI treatment
for heart failure. This case further supported the efficacy and safety of ARNI in HD patients …

… Thus, the Sacubitril/Valsartan in PriMAry preventIoN of the cardiotoxicity of … the efficacy and
safety of sacubitril/valsartan in the prevention of cardiotoxicity in early breast cancer patients …

… Moreover, safety and tolerance should be individually assessed in each LVEF … efficacy
and safety of sacubitril/valsartan. However, the evidence regarding the use of sacubitril/valsartan …

… We report on a population of 322 HF-rEF patients (75% male patients) switched to
sacubitril-valsartan. Of this total cohort, 25 patients were in the titration phase at the time of data …

… Conclusions: This study of patients admitted with HF and started on sacubitril/valsartan … is
to assess the safety and tolerability of sacubitril/valsartan when initiated in HF patients. Primary …

… -degrading enzyme, and an angiotensin II type 1 receptor blocker (valsartan), suppresses
renal injury in a pre-clinical model of early DN more effectively than valsartan monotherapy. …

… With regard to tolerability, most AEs reported in this study were mild to moderate in severity,
… To the best of our knowledge, this is the first study to investigate the efficacy and tolerability …

… the efficacy and safety of sacubitril/valsartan vs. olmesartan in Japanese patients with
mild-to-moderate essential … in BP among patients treated with 200 mg sacubitril/valsartan (−18.21 …

… an analysis of the sacubitril/ valsartan safety and tolerability profile. … effectiveness of
sacubitril/valsartan will pave the way for widespread utilization of this treatment in Polish patients, …